Clinical Trial Update: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection [Phase 3]

View source ↗

Summary

Phase 3 trial update of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with low-dose ribavirin in genotype 1a chronic hepatitis C, completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with low-dose ribavirin

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED | Results posted: 2017-10-18